Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - aztreonam - injection, powder, for solution - 1 g/vial - aztreonam 1 g/vial

Australia - English - Department of Health (Therapeutic Goods Administration)

aztreonam -

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol -

Australia - English - Department of Health (Therapeutic Goods Administration)

cs ethical pty ltd - shark sodium chondroitin sulfate, quantity: 400 mg - capsule, hard - excipient ingredients: magnesium stearate; quinoline yellow; titanium dioxide; indigo carmine; gelatin - decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - aztreonam, quantity: 1 g - injection, powder for - excipient ingredients: arginine - indications as at 23 may 1991: 1. azactam is indicated for use as a single agent in the treatment of infections known or strongly suspected to be due to susceptible gram negative aerobes, such as urinary tract infection, gonorrhoea, etc. 2. in combination with other suitable antibiotics to treat serious infections due to problem organisms known or likely to be susceptible to aztreonam. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an aminoglycoside because of synergistic action. however, this enhanced activity is not predictable. if such concurrent therapy is considered in patients with serious infections, susceptibility tests should be performed in vitro to determine the activity of the drugs in combination. because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics, renal function should be monitored according to the aminoglycoside manufacturer's prescribing information, especially if high dosages of the aminoglycoside are to be u

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - aztreonam 1 g; aztreonam 1 g - powder for injection - 1 g - active: aztreonam 1 g excipient: arginine active: aztreonam 1 g excipient: arginine - for the treatment of infections caused by susceptible gram-negative microorganisms. it has been used successfully to treat: urinary tract infections (including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to the pathogens resistant to the aminoglycosides, cephalosporins or penicillins); lower respiratory tract infections (including pneumonia and bronchitis); bacteraemia/septicemia; bone and joint infections; skin and skin-structure infections (including those associated with postoperative wounds, ulcers and burns); intra-abdominal infections (including peritonitis); gynaecologic infections (including pelvic inflammatory disease, endometritis, and pelvic cellulitis); gonorrhoea (acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of n.gonorrhoeae). before instituting treatment with azactam, appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to aztreonam. treatment with azactam may be started empirically before results of the susceptibility testing are available. concurrent therapy: in seriously ill patients, additional antibiotic therapy should be initiated concurrently with azactam to provide broad-spectrum coverage before identification and susceptibility testing results of the causative organism(s) are known. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an amino-glycoside because of synergistic action. these agents are also synergistic in vitro against many strains of enterobacteriaceae, and other gram-negative aerobic baccilli. however, this enhanced activity is not predictable.

Ireland - English - HPRA (Health Products Regulatory Authority)

ibsa farmaceutici italia s.r.l - chondroitin sulfate - capsule, hard - 400 milligram(s) - antiinflammatory and antirheumatic products

Canada - English - Health Canada

hoffmann-la roche limited - ceftriaxone (ceftriaxone sodium) - powder for solution - 250mg - ceftriaxone (ceftriaxone sodium) 250mg - third generation cephalosporins

Canada - English - Health Canada

hoffmann-la roche limited - ceftriaxone (ceftriaxone sodium) - powder for solution - 2g - ceftriaxone (ceftriaxone sodium) 2g - third generation cephalosporins

Canada - English - Health Canada

hoffmann-la roche limited - ceftriaxone (ceftriaxone sodium) - powder for solution - 1g - ceftriaxone (ceftriaxone sodium) 1g - third generation cephalosporins